Segrist E, Cherry S
Cell Host Microbe. 2020; 27(3):329-344.
PMID: 32164844
PMC: 7735531.
DOI: 10.1016/j.chom.2020.02.003.
Aravamudhan P, Raghunathan K, Konopka-Anstadt J, Pathak A, Sutherland D, Carter B
PLoS Pathog. 2020; 16(2):e1008380.
PMID: 32109948
PMC: 7065821.
DOI: 10.1371/journal.ppat.1008380.
Brown J, Short S, Stencel-Baerenwald J, Urbanek K, Pruijssers A, McAllister N
J Virol. 2018; 92(10).
PMID: 29514905
PMC: 5923068.
DOI: 10.1128/JVI.02062-17.
Berger A, Mainou B
Viruses. 2018; 10(1).
PMID: 29301335
PMC: 5795432.
DOI: 10.3390/v10010019.
Berger A, Yi H, Kearns D, Mainou B
PLoS Pathog. 2017; 13(12):e1006768.
PMID: 29211815
PMC: 5734793.
DOI: 10.1371/journal.ppat.1006768.
Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A, Johnston R, Shmulevitz M
Viruses. 2015; 7(12):6251-78.
PMID: 26633466
PMC: 4690860.
DOI: 10.3390/v7122936.
Effects of Mycotoxins on mucosal microbial infection and related pathogenesis.
Park S, Kim D, Kim J, Moon Y
Toxins (Basel). 2015; 7(11):4484-502.
PMID: 26529017
PMC: 4663516.
DOI: 10.3390/toxins7114484.
A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb E, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T
Pediatr Blood Cancer. 2015; 62(5):751-8.
PMID: 25728527
PMC: 4376570.
DOI: 10.1002/pbc.25464.
Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.
Mohamed A, Teicher C, Haefliger S, Shmulevitz M
J Virol. 2015; 89(8):4319-34.
PMID: 25653434
PMC: 4442378.
DOI: 10.1128/JVI.03651-14.
Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V, Khan K, Pandha H, Rudman S, Coffey M, Gill G
Clin Cancer Res. 2014; 21(6):1305-12.
PMID: 25424857
PMC: 4821068.
DOI: 10.1158/1078-0432.CCR-14-1770.
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov D, Nuovo G, Stiff A, Mace T, Lesinski G, Benson Jr D
Clin Cancer Res. 2014; 20(23):5946-55.
PMID: 25294913
PMC: 4253985.
DOI: 10.1158/1078-0432.CCR-14-1404.
Nonstructural protein σ1s mediates reovirus-induced cell cycle arrest and apoptosis.
Boehme K, Hammer K, Tollefson W, Konopka-Anstadt J, Kobayashi T, Dermody T
J Virol. 2013; 87(23):12967-79.
PMID: 24067959
PMC: 3838159.
DOI: 10.1128/JVI.02080-13.
Mechanisms of reovirus bloodstream dissemination.
Boehme K, Lai C, Dermody T
Adv Virus Res. 2013; 87:1-35.
PMID: 23809919
PMC: 4603565.
DOI: 10.1016/B978-0-12-407698-3.00001-6.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E, Markovic S, Suman V, Nuovo G, Vile R, Kottke T
Mol Ther. 2012; 20(10):1998-2003.
PMID: 22871663
PMC: 3464629.
DOI: 10.1038/mt.2012.146.
Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus.
Pfeiffer J
Adv Virus Res. 2010; 77:85-118.
PMID: 20951871
PMC: 3234684.
DOI: 10.1016/B978-0-12-385034-8.00004-1.
Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus.
Antar A, Konopka J, Campbell J, Henry R, Perdigoto A, Carter B
Cell Host Microbe. 2009; 5(1):59-71.
PMID: 19154988
PMC: 2642927.
DOI: 10.1016/j.chom.2008.12.001.
Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus.
Johansson C, Wetzel J, He J, Mikacenic C, Dermody T, Kelsall B
J Exp Med. 2007; 204(6):1349-58.
PMID: 17502662
PMC: 2118611.
DOI: 10.1084/jem.20061587.
A focused salivary gland infection with attenuated MCMV: an animal model with prevention of pathology associated with systemic MCMV infection.
Pilgrim M, Kasman L, Grewal J, Bruorton M, Werner P, London L
Exp Mol Pathol. 2007; 82(3):269-79.
PMID: 17320076
PMC: 3506192.
DOI: 10.1016/j.yexmp.2006.12.010.
Experimental intestinal reovirus infection of mice: what we know, what we need to know.
Montufar-Solis D, Klein J
Immunol Res. 2006; 33(3):257-65.
PMID: 16462002
PMC: 2745836.
DOI: 10.1385/IR:33:3:257.
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus.
Murray J, Mavrakis M, McDonald N, Yilla M, Sheng J, Bellini W
J Virol. 2005; 79(18):11742-51.
PMID: 16140752
PMC: 1212642.
DOI: 10.1128/JVI.79.18.11742-11751.2005.